SEEGER WEISS LLP
550 Broad Street, Suite 920
Newark, NJ 07102
Telephone: (973) 639-9100
Plaintiffs' Liaison Counsel

FILED

JAN 04 2013

Carol E. Higbee, P.J.Cv.

	SUPERIOR COURT OF NEW JERSEY LAW DIVISION: ATLANTIC COUNTY
In re: ACCUTANE LITIGATION	Civil Action Case No.271 Accutane® Multicounty Litigation **ORDER**

THIS MATTER, having come before the Court upon application by Plaintiffs and the Court having considered the arguments of counsel at the November 14, 2012 case management conference, and for good cause shown,

IT IS on this 4 day of January, 2013,

ORDERED as follows:

1. Within 60 days of the date of this order, Defendants Hoffmann-La Roche Inc. and Roche Laboratories Inc. ("Roche") and Plaintiffs shall identify all scientific research, investigation, and study activities (including any manuscript commissioning, preparation, or review) concerning or relating to isotretinoin, any other retinoid, ulcerative colitis, Crohn's disease, or inflammatory bowel disease initiated from 2003 to present (collectively, "research activities") that Roche and/or its affiliates have in any way authorized, suggested, guided, directed, approved, participated in, supported (e.g., through provision of in-kind or financial support, including but not limited to resources, data, personnel, drugs, monetary compensation, consulting payments, contractual terms, non-monetary compensation, parallel support , departmental or general grants, or restricted or unrestricted funding), regardless of whether such authorization, suggestion, guidance, direction, approval, participation, or in-kind/financial support has been direct or indirect, or employed the use of intermediaries.

2. For each such research activity identified pursuant to paragraph 1, Roche shall provide:

(a) a description of the research activity, including a detailed description of the role and involvement of Roche and/or its affiliates with the research activity and the dates of involvement;

(b) the full identity and affiliation of employees and agents of Roche and/or its affiliates who in any way participated in the research activity, together with the extent of their involvement;

(c) the identity and affiliation of any non-employees with whom Roche and its affiliates interacted in connection with the research activity, and the nature of their involvement;

(d) the identity of any intermediary that in any way participated in the research activity, and the nature of their involvement;

(e) the nature and quantum of any support, in-kind, financial or otherwise, direct or indirect, provided for such research activity; and

(f) copies of all documents concerning or reflecting items 2(a) through (f) or the Bates Numbers for any such documents that have previously been produced.

3. Within 60 days of the date of this order, Roche shall identify all agents, independent contractors, consultants, third parties, firms, operatives, public affairs firms, lobbyist firms, government relations firms, litigation firms, and crisis management firms, compensated, contracted with, or retained by or on behalf of Roche and its affiliates to facilitate, oversee, plan, direct, review, or consult on any research activity as defined in paragraph one.

4. For each such individual/entity identified pursuant to paragraph 3, Roche shall provide:

(a) a description of the research activity in which the individual/entity was involved, including a detailed description of the role and involvement of the individual/entity with the research activity and the dates of involvement;

(b) the full identity of all affiliates of the individual/entity;

(b) a description of the nature of involvement by Roche and/or its affiliates in the research activity;

(c) the full identity and affiliation of employees and agents of Roche and/or its affiliates who in any way participated in the research activity, together with the extent of their involvement;

(d) the identity and affiliation of any non-employees with whom Roche and/or its affiliates interacted in connection with the research activity, and the

nature of their involvement;

(e) the identity of any intermediary that in any way participated in the research activity, and the nature of their involvement;

(f) the nature and quantum of any support, financial or otherwise, direct or indirect, provided for such research activity; and

(g) the compensation paid to such individual/entity for each such service provided.

(h) copies of all documents concerning or reflecting items 4(a) through (g) or the Bates Numbers for any such documents that have previously been produced.

AND IT IS FURTHER ORDERED that a copy of this Order shall be served upon all parties upon receipt.



Honorable Carol E. Higbee, P.J.Cv.